(¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ º´Çà) 2021 Çѱ¹¸Á¸·ÇÐȸ ÇÏ°èÇмú´ëȸ : 2021-06-04±³À°ÀÏÀÚ : 2021-06-04
±³À°Àå¼Ò : ¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ µ¿½Ã °³ÃÖ (*¿ÀÇÁ¶óÀÎ: ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï ÄÚ¿¢½º B1 ºñ¹Ùü·ë)
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ º´Çà) 2021 Çѱ¹¸Á¸·ÇÐȸ ÇÏ°èÇмú´ëȸ ÁÖÃÖ±â°ü : ´ëÇѾȰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Çѱ¹¸Á¸·ÇÐȸ
´ã´çÀÚ : ¹ÚÀ±Á¤
¿¬¶ôó : 02-471-6520
À̸ÞÀÏ :
retina@retina.or.kr ±³À°Á¾·ù : ¾È°ú
Âü¼®¿¹»óÀοø : 250¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 5 ½Ã°£ 48ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06¿ù 04ÀÏ 13:05~13:25 Where steroids fit for DME in the Anti-VEGF era? »ç°ø¹Î(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 13:25~13:40 Non-infectious uveitis¿¡¼ ¿ÀÀúµ¦½º¢ç¿Í È޹̶ó¢çÀÇ Ä¡·áÀû À§Ä¡¿Í ½ÇÁ¦ ÀÓ»ó Àû¿ë ¿ì¼¼ÁØ(¼¿ïÀÇ´ë)
Åä·Ð 06¿ù 04ÀÏ 13:40~13:50 Discussion »ç°ø¹Î¿ì¼¼ÁØ(¿µ³²ÀǴ뼿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 13:50~14:00 Heterogeneity of Inherited Cone Dysfunction Disorders with Normal Fundus appearance ÁÖ±¤½Ä(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 14:00~14:10 Retinitis Pigmentosa Sine Pigmento: Clinical Spectrum and Pigment Development ÀÌÀº°æ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 14:10~14:20 Myopic Disc Deformation as a Prognostic Factor of Myopic Choroidal Neovascularization: A 6-year Follow-up Study ±èÀ±Àü(¿ï»êÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 14:20~14:30 Clinical features of wide macular posterior staphyloma: Primary versus Compound staphyloma ¹Ú¿îö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 14:30~14:40 Therapeutic Efficacy of Autologous Platelet Concentrate on Macular hole with High myopia, Large Macular Hole or Recurrent Macular Hole: A Multicenter Randomized Clinical Trial ¹Ú¿µÈÆ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 14:40~14:50 Ȳ¹Ý¿ø°ø ¼ö¼ú ÈÄ È²¹ÝÀÇ º¯Çü°ú º¯Çü½Ã ÀÌÁöÀº(À̾ȰúÀÇ¿ø)
±³À°½Ã°£ 06¿ù 04ÀÏ 14:50~15:00 ¼Ò¾Æ ¸Á¸· ȯÀÚÀÇ Àü½Å¸¶ÃëÇÏ °Ë»ç (Exam under anesthesia; EUA) ±è»óÁø(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 15:05~15:15 ÀÎü À¯·¡ ¸Á¸· ¿À°¡³ëÀÌµå ³» ¸Á¸· ½Å°æÀý ¼¼Æ÷ÃþÀÇ Çü¼º ¹× lamination¿¡¼ mTORC1 °æ·ÎÀÇ ¿ªÇÒ ±Ô¸í ÇÑÁ¤¿ì(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 15:15~15:25 Relationship between retinal capillary vessel density of OCT angiography and intraocular pressure in pig ÃÖ¹ÌÇö(°í·ÁÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 15:25~15:35 Impact of Kidney Transplantation on the Risk of Retinal Vein Occlusion in End-stage Renal Disease ¿À¹é·Ï(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 15:35~15:45 Retinal Vascular Occlusion in Moyamoya Disease: Case series and Literature Review À̽±Ô(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 15:45~15:55 Deep learning-based cardiovascular risk stratification using coronary artery calcium scores predicted from retinal photographs ÀÓÇüÅÃ(SERI)
±³À°½Ã°£ 06¿ù 04ÀÏ 15:55~16:05 Customized Color Settings of Digitally Assisted Vitreoretinal Surgery Enable a Decrease in the Dye Concentration during Macular Surgery ¹Úµ¿È£(°æºÏÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 16:10~16:16 ¿À¿° Á¡Åº¹°Áú¿¡ ÀÇÇØ Áý´Ü¹ß»ýÇÑ ¼ú ÈÄ Çª»ç¸®¿ò Áø±Õ ¾È³»¿° ȯÀÚ¿¡¼ ÀÌÂ÷ Àΰø¼öÁ¤Ã¼ »ðÀÔ¼ú ±èÁß°ï(¿ï»êÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 16:16~16:22 Successful PVD induction; The outcome of vitreous surgery depends a lot on the accomplishment of this procedure À̺´·Î(ÇѾçÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 16:22~16:28 New Method of Macular hole surgery by drawing macula ¿ÀÇö¼·(´©³×¾È°ú)
±³À°½Ã°£ 06¿ù 04ÀÏ 16:28~16:34 Retinal toxicity due to long-standing migratory perfluorocarbon ½Å¿ë¿î(ÇѾçÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 16:34~16:40 Å« ¸Æ¶ô¸· Èæ»öÁ¾ÀÇ ¼ö¼úÀû Ä¡·á ±è¹Î(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 16:40~16:46 Ȳ¹ÝÇÏ Á¶Á÷ Çö󽺹̳ë°Õ È°¼ºÀÎÀÚ¿Í °ø±â ÁÖÀÔ¼úÀ» ÅëÇÑ ¸Á¸·ÇÏ ÃâÇ÷ÀÇ È£Àü »ç·Ê ÀÌÇü¿ì(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 16:46~16:52 4±ºµ¥ Á¢ÇպΠ·»Áî °ø¸·°íÁ¤¼úÀ» ½±°Ô ¼öÇàÇÏ´Â ¹æ¹ý ¹Ú¹Î¼±(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 16:52~16:58 Acute intraoperative hypotony: Cause, Management and Prevention Àå¿ìÇõ(Àå¿ìÇõ¾È°ú)
±³À°½Ã°£ 06¿ù 04ÀÏ 16:58~17:04 ¹Ì¼÷¾Æ¸Á¸·º´Áõ¿¡¼ÀÇ Ç×Ç÷°ü³»ÇǼºÀåÀÎÀÚ ÁÖ»çÄ¡·á½Ã À¯ÀÇÇØ¾ß ÇÒ Á¡ ÀåÁöÇý(°è¸íÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 17:04~17:10 Long-Term Follow-Up of Peripheral Pigmentary Retinopathy in Asian Patients with Danon Disease ÀÌÁÖ¿ë(¿ï»êÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 17:15~17:21 In exudative AMD, SRF should be eliminated ±èÀçÈÖ(±è¾È°ú)
±³À°½Ã°£ 06¿ù 04ÀÏ 17:21~17:27 In exudative AMD, SRF can be tolerated »ç°ø¹Î(¿µ³²ÀÇ´ë)
Åä·Ð 06¿ù 04ÀÏ 17:27~17:32 Discussion ±èÀçÈÖ»ç°ø¹Î(±è¾È°ú¿µ³²ÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 17:32~17:38 Áõ½Ä´ç´¢¸Á¸·º´Áõ ¼ö¼ú½Ã anti-VEGF ÁÖ»ç´Â ¾ðÁ¦Çϳª? : ±èÁ¤¿(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 17:38~17:44 Áõ½Ä´ç´¢¸Á¸·º´Áõ ¼ö¼ú½Ã anti-VEGF ÁÖ»ç´Â ¾ðÁ¦Çϳª? : ¾ÈÁöÀ±(¼¿ïÀÇ´ë)
Åä·Ð 06¿ù 04ÀÏ 17:44~17:49 Discussion ±èÁ¤¿¾ÈÁöÀ±(Ãæ³²ÀǴ뼿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 17:49~17:55 ERM ¼ö¼ú ¾ðÁ¦ Çϳª?: ¡°½Ã·Â ÀúÇÏ µî Áõ»óÀÌ ÀÖÀ» ¶§±îÁö ±â´Ù¸°´Ù¡± ±èÁß°ï(¿ï»êÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 17:55~18:01 ERM ¼ö¼ú ¾ðÁ¦ Çϳª?: ¡°Áõ»óÀÌ ¶Ñ·ÇÇØÁö±â Àü¿¡ Á¶±â Á¦°ÅÇÑ´Ù¡± À̼ºÁø(¼øõÇâÀÇ´ë)
Åä·Ð 06¿ù 04ÀÏ 18:01~18:06 Discussion ±èÁß°ïÀ̼ºÁø(¿ï»êÀÇ´ë¼øõÇâÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 18:06~18:12 ¿°ø¸Á¸·¹Ú¸®¿¡¼ ¸Á¸·ÇϾ×ÀÇ ¹è¾×À» À§ÇÑ ÃÖÀûÀÇ ¼ú±â´Â? : ¹Ú¿îö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 18:12~18:18 ¿°ø¸Á¸·¹Ú¸®¿¡¼ ¸Á¸·ÇϾ×ÀÇ ¹è¾×À» À§ÇÑ ÃÖÀûÀÇ ¼ú±â´Â? : ±èö±¸(±è¾È°ú)
Åä·Ð 06¿ù 04ÀÏ 18:18~18:23 Discussion ¹Ú¿îö±èö±¸(¼¿ïÀÇ´ë±è¾È°ú)
±³À°½Ã°£ 06¿ù 04ÀÏ 18:25~18:40 Proactive treatment in nAMD ±è¹Î(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06¿ù 04ÀÏ 18:40~18:55 Early intensive treatment in DME ¹Ú¿µÈÆ(°¡Å縯ÀÇ´ë)
Åä·Ð 06¿ù 04ÀÏ 18:55~19:10 Discussion ±è¹Î¹Ú¿µÈÆ(¿¬¼¼ÀÇ´ë°¡Å縯ÀÇ´ë)